Perkins Capital Management Inc. Has $3.01 Million Stock Position in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Perkins Capital Management Inc. trimmed its stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 3.4% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 32,636 shares of the medical instruments supplier’s stock after selling 1,150 shares during the period. LeMaitre Vascular accounts for 2.7% of Perkins Capital Management Inc.’s portfolio, making the stock its 9th largest position. Perkins Capital Management Inc. owned 0.15% of LeMaitre Vascular worth $3,007,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently made changes to their positions in the stock. Bridge City Capital LLC increased its position in LeMaitre Vascular by 7.3% during the 4th quarter. Bridge City Capital LLC now owns 94,471 shares of the medical instruments supplier’s stock valued at $8,705,000 after buying an additional 6,430 shares in the last quarter. KLP Kapitalforvaltning AS acquired a new position in LeMaitre Vascular during the 4th quarter valued at about $811,000. Sei Investments Co. increased its position in LeMaitre Vascular by 9.6% during the 4th quarter. Sei Investments Co. now owns 96,857 shares of the medical instruments supplier’s stock valued at $8,924,000 after buying an additional 8,494 shares in the last quarter. Teacher Retirement System of Texas increased its holdings in shares of LeMaitre Vascular by 31.8% in the fourth quarter. Teacher Retirement System of Texas now owns 101,851 shares of the medical instruments supplier’s stock valued at $9,385,000 after purchasing an additional 24,586 shares during the period. Finally, Envestnet Portfolio Solutions Inc. raised its stake in shares of LeMaitre Vascular by 10.1% in the fourth quarter. Envestnet Portfolio Solutions Inc. now owns 3,440 shares of the medical instruments supplier’s stock worth $317,000 after purchasing an additional 315 shares during the last quarter. 84.64% of the stock is owned by institutional investors.

LeMaitre Vascular Trading Down 2.6 %

Shares of LMAT opened at $83.49 on Monday. LeMaitre Vascular, Inc. has a 12 month low of $62.39 and a 12 month high of $109.58. The stock’s 50 day moving average is $94.32 and its two-hundred day moving average is $94.52. The firm has a market cap of $1.88 billion, a P/E ratio of 45.62, a PEG ratio of 2.22 and a beta of 0.89.

LeMaitre Vascular (NASDAQ:LMAT) last issued its quarterly earnings data on Thursday, February 27th. The medical instruments supplier reported $0.49 EPS for the quarter, meeting the consensus estimate of $0.49. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. The company had revenue of $55.81 million for the quarter, compared to analyst estimates of $55.99 million. Equities research analysts forecast that LeMaitre Vascular, Inc. will post 1.94 EPS for the current year.

LeMaitre Vascular Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, March 27th. Shareholders of record on Thursday, March 13th will be issued a $0.20 dividend. This is a positive change from LeMaitre Vascular’s previous quarterly dividend of $0.16. This represents a $0.80 annualized dividend and a yield of 0.96%. The ex-dividend date of this dividend is Thursday, March 13th. LeMaitre Vascular’s dividend payout ratio (DPR) is presently 41.24%.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the company. Oppenheimer cut LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research note on Friday, February 28th. StockNews.com cut LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Friday, December 13th. Barrington Research cut LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research note on Friday, February 28th. Wells Fargo & Company assumed coverage on LeMaitre Vascular in a report on Thursday, February 13th. They set an “equal weight” rating and a $95.00 target price on the stock. Finally, Lake Street Capital raised their target price on LeMaitre Vascular from $105.00 to $110.00 and gave the stock a “buy” rating in a report on Friday, February 28th. Five equities research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $95.25.

Insider Transactions at LeMaitre Vascular

In other news, insider Trent G. Kamke sold 2,009 shares of LeMaitre Vascular stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $82.12, for a total value of $164,979.08. Following the sale, the insider now directly owns 5,564 shares of the company’s stock, valued at $456,915.68. The trade was a 26.53 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 10.79% of the company’s stock.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.